Musgrove Park Hospital | ClinicalTrials HQ

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.	Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm	Recruiting	Phase 3	2026-09-25		NCT06758401
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, male breast carcinoma, neoplasm, skin disorder	Recruiting	Phase 3	2026-09-15		NCT06492616
The Early Valve Replacement in Severe ASYmptomatic Aortic Stenosis Study	Ventricular Outflow Obstruction, aortic valve disorder, aortic valve stenosis, cardiovascular disorder, heart disorder, heart valve disorder	Recruiting	Not applicable	2026-07-21		NCT04204915
RCT of Implantable Defibrillators in Patients With Non Ischemic Cardiomyopathy, Scar and Severe Systolic Heart Failure	cardiovascular disorder, heart disorder, heart failure	Recruiting	Not applicable	2026-06-16		NCT05568069
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease	Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Unilateral Breast Neoplasms, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 3	2026-05-19		NCT06760637
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.	Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Unilateral Breast Neoplasms, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Recruiting	Phase 3	2026-05-06		NCT07062965
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder	Active, not recruiting	Phase 3	2026-04-24		NCT03155997
Improving Radical Treatment Through MRI Evaluation of Pelvic Sigmoid Cancers	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Postoperative Complications, cancer, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder	Recruiting	Not applicable	2024-10-17		NCT02222844
Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer	Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder	Recruiting	Not stated	2024-06-14		NCT04050345
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy	Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder	Active, not recruiting	Phase 2 / Phase 3	2023-04-18		NCT00268476